Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL29625842 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL429520 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL41748 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7141021 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1377516 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405853 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7137387 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL6052999 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL405855 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543502 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190242892-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-08-08 | — | — | US | claimed |
| US-20140030262-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-01-30 | — | — | US | claimed |
| US-20100092478-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | claimed |
| US-20240060975-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-02-22 | — | — | US | disclosed |
| US-20220196652-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-06-23 | — | — | US | disclosed |
| US-20200393462-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200383905-A1 | INTRAVENOUS ADMINISTRATION OF TRAMADOL | REVOGENEX IRELAND LTD. (IE) | 2020-12-10 | — | — | US | disclosed |
| US-20200383904-A1 | INTRAVENOUS ADMINISTRATION OF TRAMADOL | REVOGENEX IRELAND LTD. (IE) | 2020-12-10 | — | — | US | disclosed |
| US-20200337988-A1 | INTRAVENOUS ADMINISTRATION OF TRAMADOL | REVOGENEX IRELAND LTD (IE) | 2020-10-29 | — | — | US | disclosed |
| US-10751279-B2 | Intravenous administration of tramadol | REVOGENEX IRELAND LTD (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10751278-B2 | Intravenous administration of tramadol | REVOGENEX IRELAND LTD (IE) | 2020-08-25 | — | — | US | disclosed |
| EP-1397126-A4 | METHOD OF DELAYING EJACULATION | DMI BIOSCIENCES INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1397126-A2 | METHOD OF DELAYING EJACULATION | DMI Biosciences, Inc. (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0996613-B1 | PURE CIS-TRAMADOL HYDROCHLORIDE PRODUCTION | RUSSINSKY LTD (IE) | 2002-10-30 | — | — | EP | disclosed |
| US-6469213-B1 | FORMING TRAMADOL MANNICH BASE, FORMING CIS-TRAMADOL BASE HYDRATE FROM THE TRAMADOL MANNICH BASE, AND FORMING CIS-TRAMADOL HYDROCHLORIDE FROM THE CIS-TRAMADOL BASE HYDRATE | RUSSINSKY LIMITED (IE) | 2002-10-22 | — | — | US | disclosed |
| WO-2002074241-A2 | METHOD OF DELAYING EJACULATION | DMI BIOSCIENCES INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020132857-A1 | Method of delaying ejaculation | ROSEWIND CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-6387956-B1 | ADMINISTERING TRAMADOL | UNIVERSITY OF CINCINNATI | 2002-05-14 | — | — | US | disclosed |
| EP-0996613-A1 | TRAMADOL, SALTS THEREOF AND PROCESS FOR THEIR PREPARATION | RUSSINSKY LIMITED (IE) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999003820-A1 | TRAMADOL, SALTS THEREOF AND PROCESS FOR THEIR PREPARATION | RUSSINSKY LIMITED (IE) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200337988-A1 | INTRAVENOUS ADMINISTRATION OF TRAMADOL | OPRK1, OPRD1, KYAT3 | OPRM1 4/4885SLC6A2 154/4885SLC6A4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.